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Abstract 
Small cell lung cancer is characterized by rapid growth and early metastasis. Despite its 
sensitivity to cytotoxic therapy, until now treatments have failed to control or cure this 
disease in most patients. Οrbital metastases are a rare manifestation of systemic 
malignancies. Breast and lung cancers represent more than two thirds of the primary cancer 
sites. Metastases to the eye and orbit develop in approximately 0.7–12% of patients with 
lung cancer. Here, we report a rare case of exophthalmos as the first manifestation of a 
metastatic carcinoma due to small cell lung cancer, and a 6-months follow-up with complete 
exophthalmic response to chemotherapy. 
 
Introduction 
Small cell lung cancer (SCLC) represents 13–20% of all new lung cancer diagnoses. It 
is the most aggressive histological subtype of lung cancer, with a strong predilection for 
early metastases [1]. The brain is a common site of metastasis in SCLC. At the initial 
diagnosis, at least 10% of the patients with SCLC already have brain metastases, brain 
metastases signal stage IV disease and generally herald an ominous prognosis, but 
neuro- and radiosurgical therapeutic evolution has resulted in effective therapeutic 
approaches, leading to improvements in neurological status and survival [2, 3].  
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Case Report 
A 69-year-old Caucasian man was admitted to the emergency unit, complaining of progressive 
exophthalmos over the past 15 days (fig. 1). His medical history included heavy smoking (108 pack-
years, until the day of admission). The patient reported fatigue without loss of weight for the last 6 
months. On physical examination, auscultation of the lungs revealed diminished breath sounds and 
dullness to percussion in the upper left lung field. 
Blood tests disclosed anemia, hematocrit 33.1% and hemoglobin 10.4 g/dl, with a pattern of 
chronic diseases. The serum chemistry findings were normal. Ophthalmologic examination confirmed 
profound exophthalmos of his right eye. Best corrected visual acuity was 20/20 in both eyes. Pupils 
were equal, round and reactive to light. The results of a neurologic examination were within normal 
limits. Chest X-ray (fig. 2a) showed a sizable mass in the left upper lobe of the lung in contact with the 
pleura. Chest computed tomography (CT) revealed a large round solid tumor with hilar and pre-
vascular lymph node enlargement. The patient underwent magnetic resonance imaging (MRI) of the 
brain and orbits to enable further evaluation. The MRI revealed a soft-tissue mass in the outer 
posterolateral wall of the right orbital cavity with infiltration of the subcutaneous fat, muscles and 
skin (fig. 3a). There were no further lesions in the brain parenchyma. A CT of the upper and lower 
abdomen also showed no metastatic lesions. In an attempt to determine the exact histopathological 
nature of the lesion, bronchoscopy was performed. The findings included a bleeding multilobar mass 
infiltrating the main carina and projection of the adjacent bronchial mucosa due to external pressure 
at the rising of the right main bronchus. Bronchial washings and transbronchial needle biopsies of the 
lung were performed. The specimen showed malignant cells consistent with SCLC cells. The patient 
additionally underwent an orbital biopsy (CT-guided fine needle aspiration biopsy) [4, 5]. The 
histological findings were identical to those of the lung mass. 
The patient was referred to the pulmonary department (oncology unit) for first-line chemotherapy 
with six regimens of cisplatin and etoposide, showing an initial complete response both at the 
primary site and the orbital metastasis (fig. 2b, 3b).  
Due to subsequent relapse to the lung, after the 4th cycle the patient underwent second-line 
chemotherapy with topotecan and carboplatine. At his last follow-up, a complete resolution of the 
exophthalmos was observed (fig. 4). He concluded six cycles with an initial partial response, but died 
2 months after the last session. Written informed consent was obtained from the patient upon 
discharge for publication of this case report and all accompanying images. 
Discussion 
SCLC represents 13–20% of all new lung cancer diagnoses [2]. It is the most 
aggressive histological subtype of lung cancer, with a strong predilection for early 
metastases [1]. The brain is a common site of metastasis in SCLC, accounting for 
approximately 70% of cases [2, 3]. At diagnosis, at least 10% of the patients already 
have brain metastases, and the majority of these will be symptomatic. They can lead to 
significant morbidity, and therefore effective therapeutic approaches are required. 
Central nervous system metastases signal stage IV disease and generally herald an 
ominous prognosis, but neuro- and radiosurgical advances have resulted in effective 
treatments of brain metastases, leading to improvement in neurological status and 
survival [6–8]. 
Οrbital metastases are a rare manifestation of systemic malignancies and account for 
only 1–13% of all orbital tumors [9–11]. However, the precise incidence of these 
lesions is difficult to estimate. It has increased in recent years because improvements in 
treatment modalities have resulted in improved survival in cancer patients. Published 
reports indicate breast and lung tumors to be the most common primary neoplasms 
leading to eye metastasis, and metastases to the eye or orbit develop in approximately  
Case Rep Ophthalmol 2011;2:360–366 
DOI: 10.1159/000334784 
Published online: 
December 2, 2011 
© 2011 S. Karger AG, Basel 
ISSN 1663–2699 
www.karger.com/cop 
 
 
 
362 
0.7–12% of patients with lung cancer [9–11]. Ophthalmologic symptoms may be 
preceded by systemic symptoms, especially if the primary site is the lung, 
gastrointestinal tract, thyroid or kidney [2]. 
The most common manifestations of orbital metastases are diplopia, exophthalmos, 
inflammation, decreased visual acuity, pain, chemosis and eyelid swelling, depending 
on the site affected. Symptoms usually occur acutely and progress rapidly, over the 
course of weeks to months [9–11]. 
The aim in treating orbital metastases is to relieve discomfort. Surgical removal of 
the mass is not recommended. Regardless of the primary tumor type, prognosis is poor 
because patients with orbital metastases are usually at an advanced stage of the 
disease. In one report, the mean survival time was 7.4 months. In another report, the 
median survival time was 1.3 years, and the two-year survival rate was 27% [4, 5]. The 
survival duration was not significantly different among patients with different types of 
primary neoplasms. 
Available treatment options of orbital metastasis are external beam radiotherapy, 
plaque radiotherapy and newer methods like surgical resection, transpupillary 
thermotherapy and intravitreal chemotherapy. Additionally, anti-vascular endothelial 
growth factor therapy can be used to slow the progress of maculopathy and neuropathy 
as well as spare vision after local radiotherapy [12–14]. 
Systemic chemotherapy alone can also be used to treat metastatic tumors to the eye 
and orbit [15]. However, chemotherapy of the primary cancer alone is not 
recommended in patients in whom the orbital lesion does not resolve with 
chemotherapy alone. In this case report, a thorough follow-up of the orbital lesion is 
presented radiographically, in combination with chemotherapy administration. 
Conclusion 
A great index of suspicion is essential when an orbital lesion appears. Even thought 
reduction in visual acuity due to orbital metastasis is rarely the first sign of lung cancer, 
the clinician should be alert. Routine annual or biannual ophthalmic examination is 
recommended for patients with underlying primary cancers to allow early detection of 
metastasis and early intervention to protect vision and maintain quality of life. 
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Fig. 1. Left: MRI of the orbits. Coronal, T2-weighted MR image demonstrates an ovoid mass-like lesion 
with high signal intensity, corresponding to lung cancer metastasis. The lesion provokes a globe 
displacement (arrow). Right: photograph of the patient. 
 
 
 
Fig. 2. Posterior-anterior chest X-rays. a Before treatment, a round mass corresponding to lung 
cancer is seen in the upper lobe of the left lung (arrow). b Six months after treatment, the round mass 
is not visible. 
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Fig. 3. Axial, enhanced, T1-weighted MR images of the orbits. a Before treatment, an ovoid well-
circumscribed, mass-like lesion which enhances homogeneously is seen within the right orbit 
(arrow). The lesion is attached to the lateral rectus muscle and is extended to the intraconal space. A 
severe globe proptosis can be noticed. b After the treatment, the mass has been decreased in size 
dramatically (arrow). The globe proptosis has been resolved. 
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Fig. 4. MRI upon admission (a), photograph upon admission (b), photograph after 3 months of 
treatment (c), and photograph after 6 months of treatment (d). 
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